X

Drug Profile

Research programme: epidermal growth factor receptor inhibitors - Centessa Pharmaceuticals

Latest Information Update: 11 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PearlRiver Bio
Developer Centessa Pharmaceuticals
Class Antineoplastics
Mechanism of Action Epidermal growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Non-small cell lung cancer

Most Recent Events

31 Mar 2022 Discontinued for Non-small cell lung cancer in Germany (unspecified route) (Centessa pipeline, April 2022)
16 Feb 2021 PearlRiver Bio has merged with Centessa Pharmaceuticals to form Centessa Pharmaceuticals
16 Feb 2021 Early research in Non-small cell lung cancer in Germany (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com